For people seeking a powerful and clinically proven option with significant weight-loss outcomes, Zepbound is among the top contenders
In a phase 1 trial by Martin and colleagues, observations at week 6 comparing tirzepatide vs once-daily liraglutide and placebo have shown that the use of the latter, provides a reduction on the desire for high-fat and high-sugar food by lowering activation in the cingulate gyri, hippocampus and orbitofrontal cortex assessed by MRI and blood-oxygen-level at these areas, meaning less appetite, early satiety, and less food craving with more reduction on weight loss at short term (181)
Best for budget-conscious patients seeking GLP-1 access
Some GLP-1s are currently approved only for the treatment of Type 2 diabetes
Each plan is created to fit seamlessly into a clients lifestyle, focusing on long-term success rather than short-term results
The solution now faces threats from bacterial contamination, temperature fluctuations, pH changes, and time itself